Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research

@article{Celada2013Serotonin5R,
  title={Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research},
  author={Pau Celada and Anal{\'i}a Bortolozzi and Francesc Casa{\~n}as Artigas},
  journal={CNS Drugs},
  year={2013},
  volume={27},
  pages={703-716}
}
Psychiatric disorders represent a large economic burden in modern societies. However, pharmacological treatments are still far from optimal. Drugs used in the treatment of major depressive disorder (MDD) and anxiety disorders (selective serotonin [5-HT] reuptake inhibitors [SSRIs] and serotonin-noradrenaline reuptake inhibitors [SNRIs]) are pharmacological refinements of first-generation tricyclic drugs, discovered by serendipity, and show low efficacy and slowness of onset. Moreover… Expand
Functional Selectivity and Antidepressant Activity of Serotonin 1A Receptor Ligands
TLDR
Identifying brain specific molecular targets for 5-HT1A receptor ligands may result in a better targeting, raising a hope for more effective medicines for various pathologies. Expand
The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants
TLDR
The novel antidepressants vortioxetine, vilazodone and milnacipran/levomilnacIPran are featured with regard to their serotonin receptor targets which may account for their specific effects on certain symptoms of depression as well as a characteristic side-effect profile. Expand
Psychopharmacology of combined activation of the serotonin1A and &sgr;1 receptors
TLDR
The findings suggest that the functional interaction between the 5‐HT1A and &sgr;1 receptors activates prefrontal dopaminergic system under the conditions of decreased brain GABAA receptor function and the neurochemical effect is linked to the behavioral effect. Expand
Revealing vilazodone's binding mechanism underlying its partial agonism to the 5-HT1A receptor in the treatment of major depressive disorder.
TLDR
This newly identified binding mechanism underlying vilazodone's partial agonism to the 5-HT1A receptor will provide valuable information for medicinal chemists working in the field of rational design of novel SPARIs for MDD treatment. Expand
A Neurobiological Hypothesis of Treatment-Resistant Depression – Mechanisms for Selective Serotonin Reuptake Inhibitor Non-Efficacy
TLDR
It is proposed that TRD may not represent a simple serotonin deficit state but rather an excess of midbrain peri-raphe serotonin and subsequent deficit at key fronto-limbic projection sites, with ultimate compromise in serotonin-mediated neuroplasticity. Expand
Potential antidepressant-like effect of piperazine derivative LQFM212 in mice: Role of monoaminergic pathway and brain-derived neurotrophic factor
Major depression disorder (MDD) is one of the most widespread and debilitating psychiatric diseases and may be associated with other mental disorders such as anxiety. Despite advances in neurobiologyExpand
Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant.
TLDR
In direct comparison to duloxetine, vortioxetine is found to have a smaller efficacy but had a lower risk of developing the common antidepressant-induced adverse effects. Expand
Similar anxiolytic effects of agonists targeting serotonin 5-HT1A or cannabinoid CB receptors on zebrafish behavior in novel environments.
TLDR
Behavioral findings suggest that azipirones, like cannabinoid agonists, have anxiolytic and/or sedative properties on fish in novel environments, and highlight the need to consider potential ecological risks of azapirones and multimodal antidepressants in the future. Expand
Chronic Treatment with the 5-HT1A Receptor Partial Agonist Tandospirone Increases Hippocampal Neurogenesis
TLDR
The results strongly suggest that 5-HT1A receptor partial agonists would be useful and beneficial in the treatment of depressive and anxiety disorders through increased hippocampal neurogenesis. Expand
Role of central serotonin and noradrenaline interactions in the antidepressants' action: Electrophysiological and neurochemical evidence.
TLDR
In this review, particular morpho-physiological aspects of these systems are first considered and principal features of central 5-HT/NA interactions are examined and future directions including novel therapeutic strategies are proposed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 213 REFERENCES
Serotonin receptors involved in antidepressant effects.
TLDR
The preclinical and clinical evidence supporting the involvement of different 5-HT receptors in the therapeutic action of antidepressant drugs is reviewed to help to identify new therapeutic targets and to overcome the two main limitations of current treatments. Expand
The role of serotonin receptor subtypes in treating depression: a review of animal studies
TLDR
The involvement of 5- HT receptors in the antidepressant-like effects of SSRIs is complex and involves the orchestration of stimulation and blockade at different 5-HT receptor subtypes. Expand
5-HT1A receptor function in major depressive disorder
TLDR
It is raised the possibility that 5-HT(1A) receptor dysfunction represents one potential mechanism underpinning MDD and other stress-related disorders. Expand
The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?
TLDR
There is now a sufficient rationale to examine thoroughly the role of the 5-HT1A receptor in schizophrenia and antipsychotic drug treatment, and the anticataleptic activity of 5- HT1A agonist augmentation of neuroleptics in the treatment of schizophrenia. Expand
Therapeutic Role of 5‐HT1A Receptors in The Treatment of Schizophrenia and Parkinson's Disease
  • Y. Ohno
  • Psychology, Medicine
  • CNS neuroscience & therapeutics
  • 2011
TLDR
Evidence that 5‐HT1A receptors seem to be a promising target for alleviating antipsychotic‐induced extrapyramidal side effects (EPS) and cognitive/affective disorders in schizophrenia and Parkinson's disease should encourage discovery of new 5‐ HT1A ligands, which can resolve the unmet clinical needs in the current therapy. Expand
Is there a role for 5-HT1A agonists in the treatment of depression?
TLDR
5-HT1A receptor agonism represents a valuable and efficacious therapeutic approach to major depression and extended-release formulations allow once-daily dosing regimens, thus avoiding sharp peak plasma concentrations and permits the use of higher dosages. Expand
Modifying 5-HT1A Receptor Gene Expression as a New Target for Antidepressant Therapy
TLDR
Down-regulation of 5-HT1A autoreceptor expression, not simply desensitization of receptor signaling, appears to be required to enhance and accelerate antidepressant action. Expand
Serotonin 5-HT1a Receptor Agonists as Antidepressants
TLDR
For 20 years serotonin 5-HT1A receptor agonists have been evaluated for effectiveness in treating depressive disorders and depressive symptoms occurring in a range of diagnostic categories, including major and minor depression, mixed states of anxiety and depression, and mixed syndromes of depression and alcohol dependence. Expand
Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
  • M. Millan
  • Medicine, Psychology
  • The Journal of pharmacology and experimental therapeutics
  • 2000
TLDR
Clinical studies of antipsychotics interacting with 5-HT(1A) receptors are required to establish their genuine pertinence to the-hopefully improved-treatment of schizophrenia. Expand
Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study.
  • J. Nash, P. Sargent, +5 authors D. Nutt
  • Psychology, Medicine
  • The British journal of psychiatry : the journal of mental science
  • 2008
TLDR
Panic disorder is associated with reduced 5-HT(1A) receptor availability, which is also known to have a key role in depression. Expand
...
1
2
3
4
5
...